Recent Updates
Recently added Catalysts

RO7830698

Phase 1

Chronic Obstructive Pulmonary Disease (COPD) | Small molecule | Other |Roche Holding AG|Last Updated: Sep 16, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindCONTROLLED
Total Trials1
Total Enrollment104

FDA Designations

No designations recorded

Clinical trial landscape

RO7830698 · 1 trial · 2 indications

Phase 1 1
NCT07822334A Study of RO7830698 in Healthy Participants and Participants With Chronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease (COPD)
NOT YET_RECRUITING104 Analytics
PHASE1NOT YET_RECRUITING
A Study of RO7830698 in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease (COPD)
NCT07822334104
Unlock trial analytics

Study Endpoints

Primary Endpoints

Part 1: Incidence and Severity of Adverse Events (AEs)
Up to approximately 50 weeks
Part 2: Incidence and Severity of AEs
Up to approximately 44 weeks
Part 1: Incidence of Dose-limiting Adverse Events (DLAEs)
Up to approximately 50 weeks
Part 2: Incidence of DLAEs
Up to approximately 44 weeks

Secondary Endpoints

Part 1 and Part 2: Plasma Concentration of RO7830698
Part 1: Up to approximately 50; Part 2: Up to approximately 44 weeks
Part 1: Bioavailability (F) of RO7830698
Up to approximately 50 weeks
Part 1: Area Under the Concentration-Time Curve From Time 0 To Infinity (AUC inf) of RO7830698
Up to approximately 50 weeks
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Part 1: Single Ascending Dose (SAD)EXPERIMENTALHealthy participants will receive single doses of RO7830698 or placebo.
Part 2: Multiple Ascending Dose (MAD)EXPERIMENTALParticipants with COPD will receive multiple doses of RO7830698 or placebo.

Interventions

NameTypeDescription
RO7830698DRUGParticipants will receive RO7830698 as per the schedule described in the protocol.
PlaceboDRUGParticipants will receive placebo as per the schedule described in the protocol.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 80 Years
SexALL
Healthy VolunteersYes

Inclusion Criteria: All participants: * Body mass index (BMI) between 18 and 32 kilograms per meter square (kg/m2) * Agreement to adhere to the contraception requirements Part 1: * Absence of evidence of any active or chronic disease Part 2: * Confirmed diagnosis of COPD for \> 6 months, as de...

Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWSep 16, 2026NCT07822334NEW_TRIAL: changed